The enzyme sulfatase has been found to be able to catalyse a reaction it was presumed to be incapable of 1, expanding our understanding of biologically critical biomolecules. The discovery ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could ...

In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...

SHP609 was supposed to correct the deficiency in the iduronate-2-sulfatase enzyme in the CNS and prevent the cognitive decline seen in some Hunter Syndrome cases. Sadly, Shire said the phase 2/3 ...

Denali Therapeutics DNLI reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa (DNL310), in 47 patients with Hunter syndrome (MPS II) over a ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Hunter syndrome is a congenital rare disease caused by a deficiency of the IDS (Iduronate-2-sulfatase) enzyme, leading to skeletal abnormalities and intellectual disability. It is reported to ...

The listing of more than one enzyme indicates a multistep process ... HSS = hydrosteroid sulfatase, KSR = ketosteroid reductase, R = reductase, scc = side-chain cleavage, SH = sulfohydrolase ...